TABLE 1

Clinical and Scintigraphic Data for Study Population

ParameterISM patients (n = 76)ICM patients (n = 56)Healthy volunteers (n = 16)
Sex (M/F)62/1443/139/7
Age (y)68 ± 12 (range, 28–89)*60 ± 13 (range, 25–87)55 ± 16 (15–71)
NYHA class1.8 ± 0.9*2.4 ± 1.0
 I3613
 II2314
 III1523
 IV26
Fractional shortening (%)25 ± 10*20 ± 1240 ± 6
LVDd (mm)57 ± 1061 ± 1345 ± 6
LVDs (mm)44 ± 11*50 ± 1529 ± 4
LVEF (%)32 ± 1130 ± 1164 ± 9
 <40%55 (72%)44 (79%)
Early H/M1.95 ± 0.411.91 ± 0.432.30 ± 0.17
Late H/M1.79 ± 0.381.71 ± 0.412.38 ± 0.29
Mean washout rate (%)34 ± 13*42 ± 1320 ± 9
 No initial uptake15  (20%)6  (11%)
Follow-up interval (mo)54 ± 31 (range, 3–84)55 ± 29 (range, 1–84)35 ± 16
Prognosis
 Survived41 (54%)33 (59%)16 (100%)
 Cardiac death28 (37%)19 (34%)0 (0%)
  Heart failure1316
  Sudden cardiac death92
  Arrhythmia11
  Acute myocardial infarction50
 Noncardiac death7 (9%)4 (7%)0 (0%)
  AAA rupture1
  Sepsis2
  BOOP1
  Cerebral infarction12
  Carcinoma11
  Acute respiratory failure1
  Unknown1
Concomitant medications
 Diuretics32 (42%)34 (61%)
 Digitalis23 (30%)*36 (64%)
 ACE inhibitors10 (13%)*24 (43%)
 β-blockers17 (22%)13 (23%)
 Nitrates72 (95%)*21 (38%)
 Calcium channel blockers41 (54%)21 (38%)
 α-blockers4 (5%)4 (7%)
  • * P < 0.05 vs. ICM patients.

  • P < 0.05 vs. healthy volunteers.

  • NYHA = New York Heart Association; LVDd = left ventricular end-diastolic dimension; LVDs = left ventricular end-systolic dimension; H/M = heart-to-mediastinum ratio; AAA = abdominal aortic aneurysm; BOOP = bronchiolitis obliterans–organizing pneumonia; ACE = angiotensin-converting enzyme.

  • Values are shown as mean ± SD.